{"transactions":[{"id":4626199,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:31:57.000Z","date":"2026-09-23","kind":"sale","planned":false,"acquired":false,"shares":4528,"price":1.61,"value":7290.08,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001598549-26-000015","document":"form4-09242026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000015/form4-09242026_080953.xml","form_type":"4"}},{"id":4626198,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:31:57.000Z","date":"2026-09-23","kind":"sale","planned":false,"acquired":false,"shares":114851,"price":1.61,"value":184910.11,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001598549-26-000015","document":"form4-09242026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000015/form4-09242026_080953.xml","form_type":"4"}},{"id":4626197,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:31:57.000Z","date":"2026-09-22","kind":"sale","planned":false,"acquired":false,"shares":1088,"price":1.65,"value":1795.2,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":4528,"source":{"system":"sec-edgar","filing":"0001598549-26-000015","document":"form4-09242026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000015/form4-09242026_080953.xml","form_type":"4"}},{"id":4626196,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T20:31:57.000Z","date":"2026-09-22","kind":"sale","planned":false,"acquired":false,"shares":27612,"price":1.65,"value":45559.8,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":114851,"source":{"system":"sec-edgar","filing":"0001598549-26-000015","document":"form4-09242026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000015/form4-09242026_080953.xml","form_type":"4"}},{"id":4624261,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-18T22:39:19.000Z","date":"2026-09-16","kind":"sale","planned":false,"acquired":false,"shares":1285,"price":1.91,"value":2454.35,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":5616,"source":{"system":"sec-edgar","filing":"0001598549-26-000013","document":"form4-09182026_100915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000013/form4-09182026_100915.xml","form_type":"4"}},{"id":4624260,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-18T22:39:19.000Z","date":"2026-09-16","kind":"sale","planned":false,"acquired":false,"shares":32607,"price":1.91,"value":62279.37,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":142463,"source":{"system":"sec-edgar","filing":"0001598549-26-000013","document":"form4-09182026_100915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000013/form4-09182026_100915.xml","form_type":"4"}},{"id":671820,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T21:05:12.000Z","date":"2026-08-27","kind":"sale","planned":false,"acquired":false,"shares":400000,"price":4.04,"value":1616000.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2033270,"source":{"system":"sec-edgar","filing":"0001598549-26-000011","document":"form4-08312026_090809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000011/form4-08312026_090809.xml","form_type":"4"}},{"id":674643,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-26T20:57:40.000Z","date":"2026-08-24","kind":"sale","planned":false,"acquired":false,"shares":10,"price":4.5,"value":45.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2433270,"source":{"system":"sec-edgar","filing":"0001598549-26-000009","document":"form4-08262026_080835.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000009/form4-08262026_080835.xml","form_type":"4"}},{"id":678516,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-21T20:59:31.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":32018,"price":4.5,"value":144081.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $4.50 to $4.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2433280,"source":{"system":"sec-edgar","filing":"0001598549-26-000007","document":"form4-08212026_080827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000007/form4-08212026_080827.xml","form_type":"4"}},{"id":678515,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-21T20:59:31.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":114700,"price":4.54,"value":520738.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $4.50 to $4.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2465298,"source":{"system":"sec-edgar","filing":"0001598549-26-000007","document":"form4-08212026_080827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000007/form4-08212026_080827.xml","form_type":"4"}},{"id":678514,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-21T20:59:31.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":45147,"price":4.76,"value":214899.72,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $4.75 to $5.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2579998,"source":{"system":"sec-edgar","filing":"0001598549-26-000007","document":"form4-08212026_080827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000007/form4-08212026_080827.xml","form_type":"4"}},{"id":679756,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":6495,"price":0.32,"value":2078.4,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and\ninvestment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":7850155,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679755,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":46,"price":0.32,"value":14.72,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":55208,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679754,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":1159,"price":0.32,"value":370.88,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1400560,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679753,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":57476,"price":0.35,"value":20116.6,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and\ninvestment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":7856650,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679752,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":409,"price":0.35,"value":143.15,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":55254,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679751,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":10255,"price":0.35,"value":3589.25,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1401719,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679750,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":253080,"price":0.38,"value":96170.4,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and\ninvestment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":7914126,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679749,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":1830,"price":0.38,"value":695.4,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":55663,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":679748,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:59:27.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":45090,"price":0.38,"value":17134.2,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1411974,"source":{"system":"sec-edgar","filing":"0001598549-26-000005","document":"form4-08202026_090822.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000159854926000005/form4-08202026_090822.xml","form_type":"4"}},{"id":689546,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":1,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":2,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":3,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":4,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-08-12T20:13:55.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1484401,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1484401},"source":{"system":"sec-edgar","filing":"0001231919-26-000869","document":"form4-08122026_080846.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000123191926000869/form4-08122026_080846.xml","form_type":"4"}},{"id":689545,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":1,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":2,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":3,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":4,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-08-12T20:13:55.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":866018,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":866018},"source":{"system":"sec-edgar","filing":"0001231919-26-000869","document":"form4-08122026_080846.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000123191926000869/form4-08122026_080846.xml","form_type":"4"}},{"id":689544,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":1,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":2,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":3,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":4,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-08-12T20:13:55.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1823238,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1823238},"source":{"system":"sec-edgar","filing":"0001231919-26-000869","document":"form4-08122026_080846.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000123191926000869/form4-08122026_080846.xml","form_type":"4"}},{"id":689543,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":1,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":2,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":3,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":4,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-08-12T20:13:55.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":3152305,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3152305},"source":{"system":"sec-edgar","filing":"0001231919-26-000869","document":"form4-08122026_080846.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000123191926000869/form4-08122026_080846.xml","form_type":"4"}},{"id":689542,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":1,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":2,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":3,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":4,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:13:55.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":2350419,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":2350419,"source":{"system":"sec-edgar","filing":"0001231919-26-000869","document":"form4-08122026_080846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000123191926000869/form4-08122026_080846.xml","form_type":"4"}},{"id":689541,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":1,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":2,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":3,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":4,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:13:55.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":4975543,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":4975543,"source":{"system":"sec-edgar","filing":"0001231919-26-000869","document":"form4-08122026_080846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000123191926000869/form4-08122026_080846.xml","form_type":"4"}},{"id":691893,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T23:52:46.000Z","date":"2026-08-07","kind":"sale","planned":false,"acquired":false,"shares":52317,"price":6.85,"value":358371.45,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.80 to $7.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2783781,"source":{"system":"sec-edgar","filing":"0001231919-26-000854","document":"form4-08102026_110837.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000123191926000854/form4-08102026_110837.xml","form_type":"4"}},{"id":691892,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T23:52:46.000Z","date":"2026-08-06","kind":"sale","planned":false,"acquired":false,"shares":10494,"price":7,"value":73458.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.90 to $7.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2836098,"source":{"system":"sec-edgar","filing":"0001231919-26-000854","document":"form4-08102026_110837.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000123191926000854/form4-08102026_110837.xml","form_type":"4"}},{"id":695292,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-08-05T21:29:25.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":3179558,"price":1.5299,"value":4864405.7842,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. (\"Ventures VII\") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. (\"Ventures VII\") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Ventures VII. 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":3179558,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":3179558},"source":{"system":"sec-edgar","filing":"0001598549-26-000002","document":"form4-08052026_090821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854926000002/form4-08052026_090821.xml","form_type":"4"}},{"id":698835,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:32:54.000Z","date":"2026-07-31","kind":"sale","planned":false,"acquired":false,"shares":1718,"price":6.85,"value":11768.3,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2846592,"source":{"system":"sec-edgar","filing":"0001231919-26-000822","document":"form4-08032026_090845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000123191926000822/form4-08032026_090845.xml","form_type":"4"}},{"id":698834,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:32:54.000Z","date":"2026-07-30","kind":"sale","planned":false,"acquired":false,"shares":114756,"price":6.93,"value":795259.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $6.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2848310,"source":{"system":"sec-edgar","filing":"0001231919-26-000822","document":"form4-08032026_090845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000123191926000822/form4-08032026_090845.xml","form_type":"4"}},{"id":739188,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:16:05.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date."}],"balance_after":28000,"derivative":{"exercise_price":4.34,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001628280-26-042861","document":"wk-form4_1781295362.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000162828026042861/wk-form4_1781295362.xml","form_type":"4"}},{"id":819039,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T22:13:16.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning March 31, 2026."}],"balance_after":75000,"derivative":{"exercise_price":0.615,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023343","document":"wk-form4_1775167994.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026023343/wk-form4_1775167994.xml","form_type":"4"}},{"id":914146,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T02:06:29.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026."}],"balance_after":35000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001628280-26-006631","document":"wk-form4_1770689187.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026006631/wk-form4_1770689187.xml","form_type":"4"}},{"id":995783,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T21:34:52.000Z","date":"2025-11-14","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":8.8,"value":1760000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.023 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2963066,"source":{"system":"sec-edgar","filing":"0001231919-25-000522","document":"form4-11182025_091144.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000123191925000522/form4-11182025_091144.xml","form_type":"4"}},{"id":1040133,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T00:14:56.000Z","date":"2025-09-11","kind":"grant","planned":false,"acquired":true,"shares":2941176,"price":1.53,"value":4499999.28,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2941176,"source":{"system":"sec-edgar","filing":"0001598549-25-000004","document":"form4-09162025_120953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000159854925000004/form4-09162025_120953.xml","form_type":"4"}},{"id":1057600,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:07:28.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":6470,"price":3.42,"value":22127.4,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":57493,"source":{"system":"sec-edgar","filing":"0001415889-25-022808","document":"form4-08222025_110825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588925022808/form4-08222025_110825.xml","form_type":"4"}},{"id":1057599,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:07:28.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":163979,"price":3.42,"value":560808.18,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1457064,"source":{"system":"sec-edgar","filing":"0001415889-25-022808","document":"form4-08222025_110825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588925022808/form4-08222025_110825.xml","form_type":"4"}},{"id":1057598,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:07:28.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":2314,"price":3.57,"value":8260.98,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the\nshares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":63963,"source":{"system":"sec-edgar","filing":"0001415889-25-022808","document":"form4-08222025_110825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588925022808/form4-08222025_110825.xml","form_type":"4"}},{"id":1057597,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-22T23:07:28.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":58642,"price":3.57,"value":209351.94,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment\npower over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1621043,"source":{"system":"sec-edgar","filing":"0001415889-25-022808","document":"form4-08222025_110825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588925022808/form4-08222025_110825.xml","form_type":"4"}},{"id":1088592,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T21:25:21.000Z","date":"2025-07-09","kind":"sale","planned":false,"acquired":false,"shares":6935,"price":7.502,"value":52026.37,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1093313,"source":{"system":"sec-edgar","filing":"0001415889-25-019677","document":"form4-07112025_090716.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925019677/form4-07112025_090716.xml","form_type":"4"}},{"id":1088591,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T21:25:21.000Z","date":"2025-07-09","kind":"sale","planned":false,"acquired":false,"shares":20065,"price":7.502,"value":150527.63,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":3163066,"source":{"system":"sec-edgar","filing":"0001415889-25-019677","document":"form4-07112025_090716.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925019677/form4-07112025_090716.xml","form_type":"4"}},{"id":1097868,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:32:14.000Z","date":"2025-07-01","kind":"sale","planned":false,"acquired":false,"shares":6422,"price":7.1226,"value":45741.3372,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1100248,"source":{"system":"sec-edgar","filing":"0001415889-25-018822","document":"form4-07022025_120710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018822/form4-07022025_120710.xml","form_type":"4"}},{"id":1097867,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:32:14.000Z","date":"2025-07-01","kind":"sale","planned":false,"acquired":false,"shares":18578,"price":7.1226,"value":132323.6628,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":3183131,"source":{"system":"sec-edgar","filing":"0001415889-25-018822","document":"form4-07022025_120710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018822/form4-07022025_120710.xml","form_type":"4"}},{"id":1097866,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:32:14.000Z","date":"2025-06-30","kind":"sale","planned":false,"acquired":false,"shares":6422,"price":6.8127,"value":43751.1594,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1106670,"source":{"system":"sec-edgar","filing":"0001415889-25-018822","document":"form4-07022025_120710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018822/form4-07022025_120710.xml","form_type":"4"}},{"id":1097865,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:32:14.000Z","date":"2025-06-30","kind":"sale","planned":false,"acquired":false,"shares":18578,"price":6.8127,"value":126566.3406,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":3201709,"source":{"system":"sec-edgar","filing":"0001415889-25-018822","document":"form4-07022025_120710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018822/form4-07022025_120710.xml","form_type":"4"}},{"id":1097864,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:32:14.000Z","date":"2025-06-27","kind":"sale","planned":false,"acquired":false,"shares":19265,"price":6.91,"value":133121.15,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1113092,"source":{"system":"sec-edgar","filing":"0001415889-25-018822","document":"form4-07022025_120710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018822/form4-07022025_120710.xml","form_type":"4"}},{"id":1097863,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:32:14.000Z","date":"2025-06-27","kind":"sale","planned":false,"acquired":false,"shares":55735,"price":6.91,"value":385128.85,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":3220287,"source":{"system":"sec-edgar","filing":"0001415889-25-018822","document":"form4-07022025_120710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018822/form4-07022025_120710.xml","form_type":"4"}},{"id":1099906,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T20:02:54.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date."}],"balance_after":9000,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001736730-25-000058","document":"wk-form4_1751054565.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000173673025000058/wk-form4_1751054565.xml","form_type":"4"}},{"id":1242522,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T00:45:56.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning February 21, 2025."}],"balance_after":35000,"derivative":{"exercise_price":2.89,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001516551-25-000020","document":"wk-form4_1740617150.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000020/wk-form4_1740617150.xml","form_type":"4"}},{"id":1379294,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-31T00:30:29.000Z","date":"2024-10-28","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the one year period beginning October 28, 2024."}],"balance_after":70000,"derivative":{"exercise_price":5.15,"expiration_date":"2034-10-27","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001516551-24-000100","document":"wk-form4_1730334622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000100/wk-form4_1730334622.xml","form_type":"4"}},{"id":1386484,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":3395816,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are held by 5AM Opportunities II, L.P. (\"5AM Opportunities\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the sole general partner of 5AM Opportunities. The Reporting Person is a managing member of Opportunities II GP and may be deemed to share voting and investment power over the shares held by 5AM Opportunities. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":302770},"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386483,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":4244770,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by 5AM Ventures VI, L.P. (\"5AM Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of 5AM Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to share voting and investment power over the shares held by 5AM Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":378463},"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386482,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Prime Preferred Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":15002166,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by 5AM Ventures VI, L.P. (\"5AM Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of 5AM Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to share voting and investment power over the shares held by 5AM Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1337592},"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386481,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":909090,"price":11,"value":9999990.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by 5AM Ventures VI, L.P. (\"5AM Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of 5AM Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to share voting and investment power over the shares held by 5AM Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":2625145,"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386480,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":302770,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are held by 5AM Opportunities II, L.P. (\"5AM Opportunities\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the sole general partner of 5AM Opportunities. The Reporting Person is a managing member of Opportunities II GP and may be deemed to share voting and investment power over the shares held by 5AM Opportunities. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":302770,"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386479,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":378463,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by 5AM Ventures VI, L.P. (\"5AM Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of 5AM Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to share voting and investment power over the shares held by 5AM Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":1716055,"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1386478,"issuer":{"id":1161,"kind":"organization","name":"Camp4 Therapeutics Corp","symbol":"CAMP"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T21:48:17.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1337592,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by 5AM Ventures VI, L.P. (\"5AM Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of 5AM Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to share voting and investment power over the shares held by 5AM Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":1337592,"source":{"system":"sec-edgar","filing":"0001104659-24-108702","document":"tm2426125-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598549/000110465924108702/tm2426125-4_4seq1.xml","form_type":"4"}},{"id":1407467,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T22:56:11.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":79,"price":6.06,"value":478.74,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.05 to $6.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":66277,"source":{"system":"sec-edgar","filing":"0001415889-24-023401","document":"form4-09132024_100908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588924023401/form4-09132024_100908.xml","form_type":"4"}},{"id":1407466,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T22:56:11.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":6.06,"value":12120.0,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.05 to $6.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1679685,"source":{"system":"sec-edgar","filing":"0001415889-24-023401","document":"form4-09132024_100908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588924023401/form4-09132024_100908.xml","form_type":"4"}},{"id":1407465,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T22:56:11.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":11758,"price":6.06,"value":71253.48,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.05 to $6.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":8167206,"source":{"system":"sec-edgar","filing":"0001415889-24-023401","document":"form4-09132024_100908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588924023401/form4-09132024_100908.xml","form_type":"4"}},{"id":1407464,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T22:56:11.000Z","date":"2024-09-11","kind":"sale","planned":false,"acquired":false,"shares":1440,"price":6.6,"value":9504.0,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":66356,"source":{"system":"sec-edgar","filing":"0001415889-24-023401","document":"form4-09132024_100908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588924023401/form4-09132024_100908.xml","form_type":"4"}},{"id":1407463,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T22:56:11.000Z","date":"2024-09-11","kind":"sale","planned":false,"acquired":false,"shares":36504,"price":6.6,"value":240926.4,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1681685,"source":{"system":"sec-edgar","filing":"0001415889-24-023401","document":"form4-09132024_100908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588924023401/form4-09132024_100908.xml","form_type":"4"}},{"id":1407462,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T22:56:11.000Z","date":"2024-09-11","kind":"sale","planned":false,"acquired":false,"shares":214556,"price":6.6,"value":1416069.6,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":8178964,"source":{"system":"sec-edgar","filing":"0001415889-24-023401","document":"form4-09132024_100908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588924023401/form4-09132024_100908.xml","form_type":"4"}},{"id":1449434,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-07-24T20:15:09.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":214692,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":214692},"source":{"system":"sec-edgar","filing":"0001415889-24-020035","document":"form4-07242024_040705.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924020035/form4-07242024_040705.xml","form_type":"4"}},{"id":1449433,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-07-24T20:15:09.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":843592,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":843592},"source":{"system":"sec-edgar","filing":"0001415889-24-020035","document":"form4-07242024_040705.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924020035/form4-07242024_040705.xml","form_type":"4"}},{"id":1449432,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-24T20:15:09.000Z","date":"2024-07-22","kind":"purchase","planned":false,"acquired":true,"shares":833333,"price":12,"value":9999996.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the shares held by Opportunities II.  Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":1182054,"source":{"system":"sec-edgar","filing":"0001415889-24-020035","document":"form4-07242024_040705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924020035/form4-07242024_040705.xml","form_type":"4"}},{"id":1449431,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-24T20:15:09.000Z","date":"2024-07-22","kind":"other","planned":false,"acquired":true,"shares":348721,"price":10.2,"value":3556954.2,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the conversion of outstanding simple agreement for future equity in the amount of $3,556,957.78 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the shares held by Opportunities II.  Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":348721,"source":{"system":"sec-edgar","filing":"0001415889-24-020035","document":"form4-07242024_040705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924020035/form4-07242024_040705.xml","form_type":"4"}},{"id":1449430,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-24T20:15:09.000Z","date":"2024-07-22","kind":"other","planned":false,"acquired":true,"shares":112966,"price":10.2,"value":1152253.2,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the conversion of outstanding simple agreement for future equity in the amount of $1,152,253.93 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":1171250,"source":{"system":"sec-edgar","filing":"0001415889-24-020035","document":"form4-07242024_040705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924020035/form4-07242024_040705.xml","form_type":"4"}},{"id":1449429,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":3,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":4,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-24T20:15:09.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":true,"shares":1058284,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":1058284,"source":{"system":"sec-edgar","filing":"0001415889-24-020035","document":"form4-07242024_040705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000141588924020035/form4-07242024_040705.xml","form_type":"4"}},{"id":1574334,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-15T20:15:09.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":10,"value":4500000.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":8393520,"source":{"system":"sec-edgar","filing":"0001415889-24-008106","document":"form4-03152024_040302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000141588924008106/form4-03152024_040302.xml","form_type":"4"}},{"id":1602495,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T21:04:27.000Z","date":"2024-02-29","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024."}],"balance_after":35000,"derivative":{"exercise_price":14.56,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001516551-24-000030","document":"wk-form4_1709586211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000030/wk-form4_1709586211.xml","form_type":"4"}},{"id":1638273,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-16T21:15:31.000Z","date":"2024-02-14","kind":"sale","planned":false,"acquired":false,"shares":136642,"price":14.9,"value":2035965.8,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.89 to $14.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein."}],"balance_after":635341,"source":{"system":"sec-edgar","filing":"0001415889-24-004111","document":"form4-02162024_040204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924004111/form4-02162024_040204.xml","form_type":"4"}},{"id":1638272,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-16T21:15:31.000Z","date":"2024-02-14","kind":"sale","planned":false,"acquired":false,"shares":688358,"price":14.9,"value":10256534.2,"ownership":{"direct":false,"nature":"By 5AMVentures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.89 to $14.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":3200634,"source":{"system":"sec-edgar","filing":"0001415889-24-004111","document":"form4-02162024_040204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924004111/form4-02162024_040204.xml","form_type":"4"}},{"id":1660939,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T21:35:05.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":5206074,"price":2.31,"value":12026030.94,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially\nowned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":7943520,"source":{"system":"sec-edgar","filing":"0001209191-24-002649","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919124002649/doc4.xml","form_type":"4"}},{"id":1661737,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T21:29:43.000Z","date":"2024-01-31","kind":"sale","planned":false,"acquired":false,"shares":82813,"price":15,"value":1242195.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein."}],"balance_after":771983,"source":{"system":"sec-edgar","filing":"0001415889-24-002295","document":"form4-02022024_090230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924002295/form4-02022024_090230.xml","form_type":"4"}},{"id":1661736,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T21:29:43.000Z","date":"2024-01-31","kind":"sale","planned":false,"acquired":false,"shares":417187,"price":15,"value":6257805.0,"ownership":{"direct":false,"nature":"By 5AMVentures VI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":3888992,"source":{"system":"sec-edgar","filing":"0001415889-24-002295","document":"form4-02022024_090230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924002295/form4-02022024_090230.xml","form_type":"4"}},{"id":1748430,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-07T01:29:02.000Z","date":"2023-11-06","kind":"grant","planned":false,"acquired":true,"shares":14110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023."}],"balance_after":20001,"derivative":{"exercise_price":3.5,"expiration_date":"2033-08-25","underlying":"Common Stock","underlying_shares":14110},"source":{"system":"sec-edgar","filing":"0001516551-23-000091","document":"wk-form4_1699320532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000091/wk-form4_1699320532.xml","form_type":"4"}},{"id":1772143,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-28T20:27:26.000Z","date":"2023-09-26","kind":"sale","planned":false,"acquired":false,"shares":32711,"price":15,"value":490665.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein."}],"balance_after":854796,"source":{"system":"sec-edgar","filing":"0001209191-23-050731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123050731/doc4.xml","form_type":"4"}},{"id":1772142,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-28T20:27:26.000Z","date":"2023-09-26","kind":"sale","planned":false,"acquired":false,"shares":164789,"price":15,"value":2471835.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":4306179,"source":{"system":"sec-edgar","filing":"0001209191-23-050731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123050731/doc4.xml","form_type":"4"}},{"id":1793934,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-30T01:36:12.000Z","date":"2023-08-25","kind":"grant","planned":false,"acquired":true,"shares":1472692,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023."}],"balance_after":1472692,"derivative":{"exercise_price":0.014,"expiration_date":"2033-08-25","underlying":"Common Stock","underlying_shares":1472692},"source":{"system":"sec-edgar","filing":"0001516551-23-000068","document":"wk-form4_1693359362.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000068/wk-form4_1693359362.xml","form_type":"4"}},{"id":1795317,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-28T20:20:16.000Z","date":"2023-08-24","kind":"sale","planned":false,"acquired":false,"shares":72876,"price":16,"value":1166016.0,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his respective pecuniary interest therein."}],"balance_after":887507,"source":{"system":"sec-edgar","filing":"0001209191-23-047514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123047514/doc4.xml","form_type":"4"}},{"id":1795316,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":3,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":4,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-28T20:20:16.000Z","date":"2023-08-24","kind":"sale","planned":false,"acquired":false,"shares":367124,"price":16,"value":5873984.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":4470968,"source":{"system":"sec-edgar","filing":"0001209191-23-047514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123047514/doc4.xml","form_type":"4"}},{"id":1799477,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-08-22T21:21:07.000Z","date":"2023-08-18","kind":"grant","planned":false,"acquired":true,"shares":426348120,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the \"Purchase Agreement\"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. (\"Ventures VII\") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners\nVII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his\npecuniary interest therein."}],"balance_after":426348120,"derivative":{"exercise_price":0.0206,"exercise_date":"2023-08-18","expiration_date":"2033-08-18","underlying":"Common Stock","underlying_shares":426348120},"source":{"system":"sec-edgar","filing":"0001516551-23-000052","document":"wk-form4_1692739248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000052/wk-form4_1692739248.xml","form_type":"4"}},{"id":1799476,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-22T21:21:07.000Z","date":"2023-08-18","kind":"grant","planned":false,"acquired":true,"shares":6389921,"price":0.0103,"value":65816.1863,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the \"Purchase Agreement\"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. (\"Ventures VII\") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the \"Purchase Agreement\"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. (\"Ventures VII\") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II.  The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II.  The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":16948799,"source":{"system":"sec-edgar","filing":"0001516551-23-000052","document":"wk-form4_1692739248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000052/wk-form4_1692739248.xml","form_type":"4"}},{"id":1799475,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-22T21:21:07.000Z","date":"2023-08-18","kind":"grant","planned":false,"acquired":true,"shares":161944872,"price":0.0103,"value":1668032.1816,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the \"Purchase Agreement\"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. (\"Ventures VII\") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the \"Purchase Agreement\"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. (\"Ventures VII\") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held  by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II.  The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":429546911,"source":{"system":"sec-edgar","filing":"0001516551-23-000052","document":"wk-form4_1692739248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000052/wk-form4_1692739248.xml","form_type":"4"}},{"id":1799474,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-22T21:21:07.000Z","date":"2023-08-18","kind":"grant","planned":false,"acquired":true,"shares":684361447,"price":0.0103,"value":7048922.9041,"ownership":{"direct":false,"nature":"By 5AM Ventures VII, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the \"Purchase Agreement\"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. (\"Ventures VII\") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The securities were purchased pursuant to a Securities Purchase Agreement, dated as of August 15, 2023 (the \"Purchase Agreement\"). The transactions contemplated by the Purchase Agreement closed concurrently with the Merger on August 18, 2023. Pursuant to the Purchase Agreement, 5AM Ventures VII, L.P. (\"Ventures VII\") purchased an aggregate of 852,696,240 shares of common stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,799 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase an aggregate of 426,348,120 shares of common stock for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are directly held by 5AM Ventures VII, L.P. (\"Ventures VII\"). 5AM Partners VII, LLC (\"Partners VII\") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners\nVII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his\npecuniary interest therein."}],"balance_after":684361447,"source":{"system":"sec-edgar","filing":"0001516551-23-000052","document":"wk-form4_1692739248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000052/wk-form4_1692739248.xml","form_type":"4"}},{"id":1799473,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-22T21:21:07.000Z","date":"2023-08-18","kind":"grant","planned":false,"acquired":true,"shares":10558878,"ownership":{"direct":false,"nature":"By 5AM Co-Investors II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger and Reorganization, dated as of August 15, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bird Rock Bio, Inc. (\"Bird Rock Bio\") and Aquila Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into Bird Rock Bio (the \"Merger\"), with Bird Rock Bio surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Bird Rock Bio's Series A preferred stock, Series B preferred stock and Series C preferred stock was converted into the right to receive 18.560295 shares of the Issuer's common stock. The Merger closed on August 18, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by 5AM Co-Investors II, L.P. (\"Co-Investors II\"). Partners II is the sole general partner of Co-Investors II.  The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II.  The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":10558878,"source":{"system":"sec-edgar","filing":"0001516551-23-000052","document":"wk-form4_1692739248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000052/wk-form4_1692739248.xml","form_type":"4"}},{"id":1799472,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-22T21:21:07.000Z","date":"2023-08-18","kind":"grant","planned":false,"acquired":true,"shares":267602039,"ownership":{"direct":false,"nature":"By 5AM Ventures II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger and Reorganization, dated as of August 15, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bird Rock Bio, Inc. (\"Bird Rock Bio\") and Aquila Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into Bird Rock Bio (the \"Merger\"), with Bird Rock Bio surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Bird Rock Bio's Series A preferred stock, Series B preferred stock and Series C preferred stock was converted into the right to receive 18.560295 shares of the Issuer's common stock. The Merger closed on August 18, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held  by 5AM Ventures II, L.P. (\"Ventures II\"). 5AM Partners II, LLC (\"Partners II\") is the sole general partner of Ventures II.  The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":267602039,"source":{"system":"sec-edgar","filing":"0001516551-23-000052","document":"wk-form4_1692739248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000052/wk-form4_1692739248.xml","form_type":"4"}},{"id":1920848,"issuer":{"id":114512,"kind":"organization","name":"Pear Therapeutics, Inc.","symbol":"PEAR"},"owners":[{"id":114513,"kind":"organization","name":"5AM Partners IV, LLC","position":1,"cik":"0001589314","reported_name":"5AM Partners IV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":114514,"kind":"organization","name":"5AM Ventures IV, L.P.","position":2,"cik":"0001589315","reported_name":"5AM Ventures IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":114515,"kind":"organization","name":"5AM Co-Investors IV, L.P.","position":3,"cik":"0001593361","reported_name":"5AM Co-Investors IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":5,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":7,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":8,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-04-12T20:51:37.000Z","date":"2023-04-10","kind":"sale","planned":false,"acquired":false,"shares":3172769,"price":0.12,"value":380732.28,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.11 to $0.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab is a managing member of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001209191-23-024105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1240357/000120919123024105/doc4.xml","form_type":"4"}},{"id":1920847,"issuer":{"id":114512,"kind":"organization","name":"Pear Therapeutics, Inc.","symbol":"PEAR"},"owners":[{"id":114513,"kind":"organization","name":"5AM Partners IV, LLC","position":1,"cik":"0001589314","reported_name":"5AM Partners IV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":114514,"kind":"organization","name":"5AM Ventures IV, L.P.","position":2,"cik":"0001589315","reported_name":"5AM Ventures IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":114515,"kind":"organization","name":"5AM Co-Investors IV, L.P.","position":3,"cik":"0001593361","reported_name":"5AM Co-Investors IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":5,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":7,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":8,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-04-12T20:51:37.000Z","date":"2023-04-10","kind":"sale","planned":false,"acquired":false,"shares":534855,"price":0.12,"value":64182.6,"ownership":{"direct":false,"nature":"By 5AM Co-Investors IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.11 to $0.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by 5AM Co-Investors IV, L.P. (\"Co-Investors IV\"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Dr. Rocklage and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-024105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1240357/000120919123024105/doc4.xml","form_type":"4"}},{"id":1920846,"issuer":{"id":114512,"kind":"organization","name":"Pear Therapeutics, Inc.","symbol":"PEAR"},"owners":[{"id":114513,"kind":"organization","name":"5AM Partners IV, LLC","position":1,"cik":"0001589314","reported_name":"5AM Partners IV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":114514,"kind":"organization","name":"5AM Ventures IV, L.P.","position":2,"cik":"0001589315","reported_name":"5AM Ventures IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":114515,"kind":"organization","name":"5AM Co-Investors IV, L.P.","position":3,"cik":"0001593361","reported_name":"5AM Co-Investors IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":5,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21275,"kind":"person","name":"DIEKMAN JOHN D","position":6,"cik":"0001240357","reported_name":"DIEKMAN JOHN D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":7,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":8,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-04-12T20:51:37.000Z","date":"2023-04-10","kind":"sale","planned":false,"acquired":false,"shares":12836489,"price":0.12,"value":1540378.68,"ownership":{"direct":false,"nature":"By 5AM Ventures IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.11 to $0.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by 5AM Ventures IV, L.P. (\"Ventures IV\"). 5AM Partners IV, LLC (\"Partners IV\") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman,  Dr. Rocklage and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-024105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1240357/000120919123024105/doc4.xml","form_type":"4"}},{"id":1923781,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-07T00:22:08.000Z","date":"2023-02-23","kind":"grant","planned":false,"acquired":true,"shares":27567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":27567,"derivative":{"exercise_price":25.28,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":27567},"source":{"system":"sec-edgar","filing":"0001209191-23-023669","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123023669/doc4.xml","form_type":"4"}},{"id":1961138,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":1,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":2,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":3,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":4,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-09T21:35:35.000Z","date":"2023-03-07","kind":"sale","acquired":false,"shares":100000,"price":8.2,"value":820000.0,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by 5AM Ventures V, L.P. (\"Ventures V\"). 5AM Partners V, LLC is the general partner of Ventures V and may be deemed to have sole investment and voting power over the shares held by Ventures V. Each of Andrew Schwab, Dr. Kush Parmar and Dr. Scott Rocklage is a Managing Member of 5AM Partners V, LLC, and may be deemed to have shared voting and dispositive power over the shares held by Ventures V. Therefore, each of Andrew  Schwab, Dr. Kush Parmar, Dr. Scott Rocklage, and 5AM Partners V, LLC may be deemed to beneficially own the shares held by Ventures V, and each disclaims beneficial ownership over the shares held by Ventures V except to the extent of his or its pecuniary interest therein. Dr. Parmar is a director of the issuer and files separate Section 16 reports."}],"balance_after":2378969,"source":{"system":"sec-edgar","filing":"0001209191-23-017533","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000120919123017533/doc4.xml","form_type":"4"}},{"id":1987482,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":4,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":6,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":7,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":8,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T21:29:55.000Z","date":"2023-02-24","kind":"other","acquired":false,"shares":496323,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000120919123013671/doc4.xml","form_type":"4"}},{"id":1987481,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":4,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":6,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":7,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":8,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T21:29:55.000Z","date":"2023-02-24","kind":"other","acquired":false,"shares":487333,"ownership":{"direct":false,"nature":"By 5AM Opportunities II, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares are held by 5AM Opportunities II, L.P. (\"Opportunities II\"). 5AM Opportunities II (GP), LLC (\"Opportunities II GP\") is the sole general partner of Opportunities II. Andrew J. Schwab and Dr. Kush Parmar are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II. Each of Opportunities II GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000120919123013671/doc4.xml","form_type":"4"}},{"id":1987480,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":24241,"kind":"organization","name":"5AM Partners VI, LLC","position":1,"cik":"0001829051","reported_name":"5AM Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24240,"kind":"organization","name":"5AM Ventures VI, L.P.","position":2,"cik":"0001753037","reported_name":"5AM Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":4,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21276,"kind":"person","name":"PARMAR KUSH","position":5,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24243,"kind":"organization","name":"5AM Opportunities II (GP), LLC","position":6,"cik":"0001873515","reported_name":"5AM Opportunities II (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24242,"kind":"organization","name":"5AM Opportunities II, L.P.","position":7,"cik":"0001844401","reported_name":"5AM Opportunities II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":8,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T21:29:55.000Z","date":"2023-02-24","kind":"other","acquired":false,"shares":3953990,"ownership":{"direct":false,"nature":"By 5AM Ventures VI, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (2)]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from footnote (1)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by 5AM Ventures VI, L.P. (\"Ventures VI\"). 5AM Partners VI, LLC (\"Partners VI\") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873515/000120919123013671/doc4.xml","form_type":"4"}},{"id":1990391,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T02:55:28.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":960383,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the \"Merger Agreement\"), by and among Imara Inc. (\"Imara\"), Enliven Therapeutics, Inc., (\"Enliven\") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the \"Merger Sub\"), provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of the Imara (the \"Merger\"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed \"Enliven Therapeutics, Inc.\" and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol \"ELVN.\""},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares held of record by 5AM Ventures Opportunities I, L.P. (5AM Opportunities). 5AM Opportunities I (GP), LLC (5AM Opportunities GP) is the general partner of 5AM Opportunities and may be deemed to have sole investment and voting power over the shares held by 5AM Opportunities. As a managing member 5AM Opportunities GP, the reporting person may be deemed to share voting and dispositive power over the shares held of record by 5AM Opportunities but disclaims beneficial ownership of the securities held of record by 5AM Opportunities except to the extent of his individual pecuniary interest therein."}],"balance_after":960383,"source":{"system":"sec-edgar","filing":"0001209191-23-013526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123013526/doc4.xml","form_type":"4"}},{"id":1990390,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":1,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T02:55:28.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":4838092,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the \"Merger Agreement\"), by and among Imara Inc. (\"Imara\"), Enliven Therapeutics, Inc., (\"Enliven\") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the \"Merger Sub\"), provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of the Imara (the \"Merger\"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed \"Enliven Therapeutics, Inc.\" and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol \"ELVN.\""},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held of record by 5AM Ventures VI, L.P. (5AM VI). 5AM Partners VI, LLC (5AM Partners) is the general partner of 5AM VI and may be deemed to have sole investment and voting power over the shares held by 5AM VI. As a managing member of 5AM Partners, the reporting person may be deemed to share voting and dispositive power over the shares held of record by 5AM VI but disclaims beneficial ownership of the securities held of record by 5AM VI except to the extent of his individual pecuniary interest therein."}],"balance_after":4838092,"source":{"system":"sec-edgar","filing":"0001209191-23-013526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123013526/doc4.xml","form_type":"4"}},{"id":2098371,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-02T15:38:15.000Z","date":"2022-11-30","kind":"other","acquired":false,"shares":982453,"ownership":{"direct":false,"nature":"5AM Opportunities I, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for..."},{"field":"shares","element":"transactionShares","label":"F2","text":"(cont. from footnote 1)...(i) $12.50 per Share, net to the stockholder in cash, without interest (the \"Cash Consideration\") and less any applicable tax withholding, plus (ii) one non-tradable contingent value right (\"CVR\")  per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for..."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the general partner of 5AM Opportunities I, L.P. (\"Opportunities I\") and may be deemed to have sole investment and voting power over the shares held by Opportunities I. Each of Andrew Schwab and Dr. Kush Parmar is a Managing Member of Opportunities GP, and may be deemed to have shared voting and dispositive power over the shares held by Opportunities I. Therefore, each of Mr. Schwab, Dr. Parmar and Opportunities GP may be deemed to beneficially own the shares held by Opportunities I.  Each of Mr. Schwab and Opportunities GP disclaims beneficial ownership over the shares held by Opportunities I except to the extent of his or its pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares are held directly by Opportunities I."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-059372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000120919122059372/doc4.xml","form_type":"4"}}],"next_cursor":"2022-12-02T15:38:15.000000Z,2098371"}